Week 144 Results of a Phase II, Randomized, Multicenter Trial Assessing the Safety and Efficacy of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS)

被引：0
|
作者：
Hauser, Stephen [1 ]
Li, David [2 ]
Calabresi, Peter [3 ]
O'Connor, Paul [4 ]
Bar-Or, Amit [5 ,6 ]
Barkhof, Frederik [7 ]
Sauter, Annette [8 ]
Leppert, David [9 ]
Masterman, Donna [8 ]
Tinbergen, Jeroen [8 ]
Kappos, Ludwig [10 ,11 ]
机构：
[1] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA
[2] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[3] Johns Hopkins Univ, Baltimore, MD USA
[4] Univ Toronto, Dept Neurol, Toronto, ON, Canada
[5] McGill Univ, Montreal Neurol Inst & Hosp, Neuroimmunol Unit, Montreal, PQ, Canada
[6] McGill Univ, Montreal Neurol Inst & Hosp, Expt Therapeut Program, Montreal, PQ, Canada
[7] Vrije Univ Amsterdam, Med Ctr, Dept Radiol, Amsterdam, Netherlands
[8] F Hoffmann La Roche Ltd, Basel, Switzerland
[9] PDCN F Hoffmann La Roche, Basel, Switzerland
[10] Univ Basel Hosp, CH-4031 Basel, Switzerland
[11] Univ Basel Hosp, Dept Biomed, CH-4031 Basel, Switzerland
来源：
NEUROLOGY | 2013年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
S31004
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis
    Damiano Paolicelli
    Alessia Manni
    Antonio Iaffaldano
    Maria Trojano
    CNS Drugs, 2020, 34 : 65 - 92
  • [32] Efficacy of a Computer-Assisted Cognitive Rehabilitation Intervention in Relapsing-Remitting Multiple Sclerosis Patients: A Multicenter Randomized Controlled Trial
    Messinis, Lambros
    Nasios, Grigorios
    Kosmidis, Mary H.
    Zampakis, Petros
    Malefaki, Sonia
    Ntoskou, Katerina
    Nousia, Anastasia
    Bakirtzis, Christos
    Grigoriadis, Nikolaos
    Gourzis, Philippos
    Papathanasopoulos, Panagiotis
    BEHAVIOURAL NEUROLOGY, 2017, 2017
  • [33] Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial
    Olsson, Tomas
    Boster, Aaron
    Fernandez, Oscar
    Freedman, Mark S.
    Pozzilli, Carlo
    Bach, Doris
    Berkani, Ouali
    Mueller, Markus S.
    Sidorenko, Tatiana
    Radue, Ernst-Wilhelm
    Melanson, Maria
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2014, 85 (11): : 1198 - 1208
  • [34] Real world efficacy and safety of teriflunomide in patients with relapsing-remitting multiple sclerosis
    Boz, C.
    Ozakbas, S.
    Terzi, M.
    Turkoglu, R.
    Akman, G.
    Efendi, H.
    Akcali, A.
    Tuncer, A.
    Yuceyar, N.
    Turan, O. F.
    Soysal, A.
    Koseoglu, M.
    Balci, B. P.
    Sevim, S.
    Altintas, A.
    Cilingir, V.
    Demirkiran, M.
    Kizilay, F.
    Altunrende, B.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 327 - 328
  • [35] Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
    Kappos, Ludwig
    Li, David
    Calabresi, Peter A.
    O'Connor, Paul
    Bar-Or, Amit
    Barkhof, Frederik
    Yin, Ming
    Leppert, David
    Glanzman, Robert
    Tinbergen, Jeroen
    Hauser, Stephen L.
    LANCET, 2011, 378 (9805): : 1779 - 1787
  • [36] Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients
    Rio, Jordi
    Rovira, Alex
    Tintore, Mar
    Sastre-Garriga, Jaurne
    Castillo, Joaquin
    Auger, Cristina
    Nos, Carlos
    Comabella, Manuel
    Tur, Carmen
    Vidal, Angela
    Montalban, Xavier
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (12) : 1602 - 1608
  • [37] Half-dose ocrelizumab in selected patients with relapsing-remitting multiple sclerosis
    Algahtani, Hussein
    Shirah, Bader
    Alqahtani, Abdulhadi
    Abdelghaffar, Nawal
    Makki, Samiah
    ACTA NEUROLOGICA BELGICA, 2024, 124 (01) : 303 - 306
  • [38] Evaluation of shorter infusion times with ocrelizumab in patients with relapsing-remitting multiple sclerosis
    Vollmer, Timothy
    Alvarez, Enrique
    Nair, Kavita
    Cohen, Jeffrey
    Boster, Aaron
    Masterman, Donna
    Pradhan, Ashish
    Musch, Bruno
    Ma, Xiaoye
    Pei, Jinglan
    Moss, Brandon
    Weinstock-Guttman, Bianca
    Bermel, Robert
    NEUROLOGY, 2019, 92 (15)
  • [39] Ocrelizumab and Cladribine have Similar Efficacy and Safety in Naive Relapsing Remitting Multiple Sclerosis Patients
    Alroughani, R.
    Al-Hashel, J.
    Ahmed, S. Farouk
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 97 - 97
  • [40] Efficacy of alemtuzumab in relapsing-remitting multiple sclerosis (RRMS) patients with highly active disease despite therapy
    Confavreux, C.
    Twyman, C. L.
    Arnold, D.
    Cohen, J.
    Coles, A. J.
    Fox, E. J.
    Hartung, H-P.
    Havrdova, E.
    Selmaj, K.
    Weiner, H.
    Miller, T.
    Lake, S. L.
    Margolin, D. H.
    Panzara, M.
    Compston, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 88 - 88
12345